+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

I

Actively Recruiting

Researchers are examining the real-world use of bempedoic acid and its fixed dose combination FDC with ezetimibe in adults with primary hypercholesterolemia both heterozygous familial and non-familial or mixed dyslipidemia. This observational study aims to better understand the risks and benefits of these treatments in Asian and Latin American populations where data is currently limited. Participants in this study are adults treated or intended to be treated with bempedoic acid or the combination pill with ezetimibe as part of their regular medical care. No drugs are administered by the study team as it is non-interventional. The study follows patients for one year after starting treatment to collect information on drug reactions and cardiovascular health. During the study, participants health data is collected, including adverse drug reactions, cardiovascular risk, cholesterol levels, inflammatory markers, and uric acid levels. Researchers will review treatment duration and any related adverse events. This follow-up lasts for one year after treatment initiation, monitoring routine clinical outcomes without additional interventions.

Age: 18Years +All Genders
38 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.

Age: 18Years - 75YearsAll GendersPhase 3
180 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.

Age: 18Years - 55YearsAll GendersPhase 2
101 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.

Age: 60Years - 85YearsAll GendersPhase 3
128 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
S

Actively Recruiting

Healthcare-associated infections HAIs are a significant issue in intensive care units ICUs, often caused by environmental contamination with multidrug-resistant organisms that remain despite regular cleaning. Researchers are evaluating two advanced disinfection methodshydrogen peroxide aerosolization and ultraviolet-C lightto reduce this contamination. This cluster-randomized, crossover trial will be conducted in 12 Brazilian ICUs to compare these methods with usual surface disinfection practices. The trial includes three sequential cleaning strategies for each ICU usual surface disinfection alone usual disinfection followed by hydrogen peroxide aerosolization at 7.9% concentration applied inside a protective tent during terminal cleaning of beds and usual disinfection followed by automated ultraviolet-C irradiation applied under the same tent. The protective tent is used to prevent exposure of adjacent beds and ICU areas to the disinfecting agents. Participants will be all patients aged 18 years and older admitted to these ICUs. Researchers will measure antimicrobial use at the ICU level over three months, daily defined doses per 100 patient-days, and secondary outcomes such as rates of HAIs, contamination by multidrug-resistant organisms, specific infections like ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and ICU length of stay costs. Safety and effectiveness of surface disinfection methods will be monitored throughout the study.

Age: 18Years +All GendersPhase Not Applicable
12 locations
I

Actively Recruiting

Researchers are investigating the effects of a 16-week program combining resistance training, group cognitive behavioral therapy, and nutritional guidance for a higher-protein diet in adults aged 60 years or older with overweight or obesity. The study aims to assess changes in body composition, muscle strength and function, vascular and metabolic health, cognitive function, psychological outcomes, quality of life, autonomy, self-care, and motivation related to exercise and eating habits. Participants with low physical activity and excess body fat are randomly assigned to one of three groups to compare the impact of adding behavioral and nutritional components to resistance training. Participants will attend resistance training sessions three times per week focusing on exercises for the upper limbs, lower limbs, and trunk, with gradually increasing intensity. One group receives only resistance training, the second group adds weekly group cognitive behavioral therapy sessions to support sustainable behavioral changes, and the third group also receives weekly nutritional guidance sessions aimed at adopting a higher-protein diet using commonly consumed foods. The nutritional program includes four progressive modules and monitors adherence through food diaries. Assessments occur before and after the 16-week intervention to evaluate changes in fat-free mass, body composition, muscle strength, metabolic markers, cognitive tests, psychological scales, quality of life, and dietary intake. The study measures include physical tests, blood tests, cognitive function evaluations, and questionnaires on mental health and motivation. These evaluations help determine whether combining psychological and nutritional strategies with resistance training offers additional health benefits for older adults with overweight or obesity.

Age: 60Years +All GendersPhase Not Applicable
1 location
I

Actively Recruiting

This research aims to evaluate whether an educational quality improvement intervention focused on antimicrobial stewardship can reduce antimicrobial use in adult patients admitted to intensive care units ICUs in Brazil. The study compares current ICU practices with those after implementing the intervention, which is based on up-to-date guidelines and aims to promote rational antimicrobial use without increasing ICU mortality or length of stay. The trial uses a stepped-wedge cluster randomized design across 10 ICUs participating in the IMPACTO-MR registry platform. The intervention includes educational sessions, cognitive aids for ICU physicians and healthcare professionals to improve decisions on antimicrobial initiation and duration, and monthly audits with feedback to the ICU teams. Each ICU starts with a control phase of usual care, then transitions to the intervention phase approximately monthly starting July 2025. The study also includes a baseline data collection period before the intervention and a phase-out period to assess lasting effects after stopping feedback. Participants are all adult patients admitted to the participating ICUs during the study. Researchers will collect monthly one-day point-prevalence surveys on antimicrobial use and monitor ICU mortality rates and length of stay over 14 months to evaluate outcomes. The study will assess the impact of the educational intervention on antimicrobial use while ensuring patient safety, with no individual informed consent required due to cluster-level data collection and minimal risk.

Age: 18Years +All GendersPhase Not Applicable
9 locations
M

Actively Recruiting

Researchers are conducting a pre-screening study to identify individuals who may qualify for Roche interventional studies focused on Alzheimers disease. This study aims to assess potential eligibility by evaluating specific biomarkers and cognitive performance, helping to select suitable participants for future clinical trials related to Alzheimers disease. Participants will undergo testing to measure the concentration of pTau217 in their blood and complete the International Shopping List Test ISLT to assess cognitive function. There is no active treatment or intervention instead, the study collects these measurements to determine potential trial eligibility. During the study, participants will have blood samples drawn and complete cognitive assessments using the ISLT. Researchers will focus on the pTau217 biomarker levels and cognitive scores as primary outcomes measured on the first day of participation. This screening process helps identify candidates for subsequent interventional Alzheimers disease trials. The study is planned to run until July 2035 and includes adults aged 50 to 90 years.

Age: 50Years - 90YearsAll GendersPhase 3
234 locations